Log in
Email Address
Password
Forgot your password?
Not Registered?

Blog Spot

SMWcroppednew

Name: Stewart Watkins, Managing Director

Company: CDDC

PETEC, owned and managed by the Centre for Process Innovation (CPI), is the national flagship facility for the development and exploitation of direct write technologies and flexible functional materials. It is one of only four such centres in the world.

Click here to read the full blog

Featured Tenant

deburca


deBurca is a software development and integration company that specialises in creating, implementing and supporting innovative applications for e-learning and eBusiness.

Click here to learn more about deBurca

Featured Opportunity
An Improved Microgripper for Cell Manipulation.

There is a growing need for individual cell manipulation in a wide range of research applications including stem cell sorting, gene and molecular delivery, cellular diagnostics, and single cell-based assays.

For further information click here

Polls



CDEP logo Durham County Council Logo

cddc European Union emblem


Oneaboutnetparknet logo


NETPark Net has received funding from Durham County Council through County Durham Development Company, and One NorthEast through the County Durham Sub Regional Partnership. Project Part-Financed by the European Union. European Regional Development Fund.

Funding boost for cancer research


Bookmark and Share Add This     Email notification Email a Friend    print Printable version

Funding boost for cancer research

2008-10-03
Newsfeed

An Oxford NHS trust has been granted nearly £1 million to fund innovative cancer research.


An Oxford NHS trust has been granted nearly £1 million to fund innovative cancer research.

Charity Breakthrough Breast Cancer has donated £919,548 to Dr Anthony Kong in order to establish a research laboratory at the Weatherall Institute of Molecular Medicine in Oxford.

Dr Kong will work in collaboration with the Breakthrough Toby Robins Breast Cancer Research Centre at the Institute of Cancer Research in London to investigate a type of breast cancer called HER2 positive, which accounts for about one in five of all 46,000 cases diagnosed each year in the UK.

This work is part of the charity's Clinical Researcher Programme, which aims to bridge the gap between laboratory research into breast cancer and the patients.

Dr Kong hopes to develop a new, more sensitive test to predict with greater accuracy whether a patient is likely to benefit from herceptin. This is a key treatment for HER2 positive breast cancer but not all patients benefit from the drug.

Dr Kong said: "This funding will not only enable me to investigate ways to treat patients more effectively, but will also help me translate my findings into direct benefits for patients more quickly, which I feel is absolutely essential."

Copyright © The Press Association 2008